natgillin/translations-raw huggingface dataset:
Following an application from Efamol Ltd, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Efalex® on coordination (Question No EFSA-Q-2008-121) [10].
Družba Efamol Ltd. je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi Efalex® na koordinacijo (vprašanje št. EFSA-Q-2008-121) [10].
The claim proposed by the applicant was worded as follows: ‘Efalex® may help maintain coordination’.
Vlagatelj je predlagal naslednjo trditev: „Efalex® lahko pomaga ohranjati koordinacijo“.
On the basis of the data presented, the Authority concluded that a cause and effect relationship had not been established between the consumption of Efalex® and the claimed effect.
Agencija je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem Efalex® in navedeno trditvijo ni utemeljena.
Following an application from Efamol Ltd, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Efalex® on concentration (Question No EFSA-Q-2008-317) [11].
Družba Efamol Ltd. je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi Efalex® na zbranost (vprašanje št. EFSA-Q-2008-317) [11].
The claim proposed by the applicant was worded as follows: ‘Efalex® may help maintain concentration’.
Vlagatelj je predlagal naslednjo trditev: „Efalex® lahko pomaga ohranjati zbranost“.
Following an application from Efamol Ltd, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Efalex® on brain development and function (Question No EFSA-Q-2008-318) [12].
Družba Efamol Ltd. je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi Efalex® na razvoj in delovanje možganov (vprašanje št. EFSA-Q-2008-318) [12].
The claim proposed by the applicant was worded as follows: ‘Efalex® may help maintain and support brain development and function’.
Vlagatelj je predlagal naslednjo trditev: „Efalex® lahko pomaga ohranjati in spodbujati razvoj in delovanje možganov“.
Following an application from Efamol Ltd, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Efalex® on learning ability (Question No EFSA-Q-2008-319) [13].
Družba Efamol Ltd. je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi Efalex® na sposobnost učenja (vprašanje št. EFSA-Q-2008-319) [13].
The claim proposed by the applicant was worded as follows: ‘Efalex® may help maintain learning ability’.
Vlagatelj je predlagal naslednjo trditev: „Efalex® lahko pomaga ohranjati sposobnost učenja“.
Following an application from Efamol Ltd, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Efalex® on eye development and function (Question No EFSA-Q-2008-320) [14].
Družba Efamol Ltd. je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi Efalex® na razvoj in delovanje oči (vprašanje št. EFSA-Q-2008-320) [14].
The claim proposed by the applicant was worded as follows: ‘Efalex® may help maintain and support eye development and function’.
Vlagatelj je predlagal naslednjo trditev: „Efalex® lahko pomaga ohranjati ter spodbujati razvoj in delovanje oči“.
Following an application from Potters Ltd, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Eye q baby® on the central nervous system development (Question No EFSA-Q-2008-119) [15].
Družba Potters Ltd. je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi Eye q baby® na razvoj centralnega živčnega sistema (vprašanje št. EFSA-Q-2008-119) [15].
The claim proposed by the applicant was worded as follows: ‘Eye q baby® provides the nourishments that support healthy central nervous system development’.
Vlagatelj je predlagal naslednjo trditev: „Eye q baby® omogoča prehrano, ki spodbuja razvoj zdravega centralnega živčnega sistema“.
On the basis of the data presented, the Authority concluded that a cause and effect relationship had not been established between the intake of Eye q baby® and the claimed effect.
Agencija je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med vnosom Eye q baby® in navedeno trditvijo ni utemeljena.
Following an application from Potters Ltd, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Eye q® on brain functions (Question No EFSA-Q-2008-329) [16].
Družba Potters Ltd. je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi Eye q® na delovanje možganov (vprašanje št. EFSA-Q-2008-329) [16].
The claim proposed by the applicant was worded as follows: ‘Eye q® provides the nourishments that help children to maintain healthy brain functions’.
Vlagatelj je predlagal naslednjo trditev: „Eye q® omogoča prehrano, ki otrokom pomaga ohranjati zdravo delovanje možganov“.
On the basis of the data presented, the Authority concluded that a cause and effect relationship had not been established between the intake of Eye q® and the claimed effect.
Agencija je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med vnosom Eye q® in navedeno trditvijo ni utemeljena.
Following an application from Potters Ltd, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Eye q® on concentration (Question No EFSA-Q-2008-330) [17].
Družba Potters Ltd. je v skladu s členom 14(1)(b) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z vplivi Eye q® na zbranost (vprašanje št. EFSA-Q-2008-330) [17].
The claim proposed by the applicant was worded as follows: ‘Eye q® provides the nourishments that help children to maintain concentration levels’.
Vlagatelj je predlagal naslednjo trditev: „Eye q® omogoča prehrano, ki otrokom pomaga ohranjati zbranost“.
The comments from the applicants and the members of the public received by the Commission pursuant to Article 16(6) of Regulation (EC) No 1924/2006 have been considered when setting the measures provided for in this Regulation.
Pri določanju ukrepov iz te uredbe so bile upoštevane pripombe, ki so jih vlagatelji in predstavniki javnosti poslali Komisiji v skladu s členom 16(6) Uredbe (ES) št. 1924/2006.
In accordance with Article 28(6) of Regulation (EC) No 1924/2006 health claims referred to in Article 14(1)(b) of Regulation (EC) No 1924/2006 and not authorised by this Regulation may continue to be used for six months after the adoption of a decision pursuant to Article 17(3) of Regulation (EC) No 1924/2006.
Zdravstvene trditve, ki so usklajene s členom 14(1)(b) Uredbe (ES) št. 1924/2006 in niso odobrene s to uredbo, se lahko v skladu s členom 28(6) Uredbe (ES) št. 1924/2006 uporabljajo šest mesecev po sprejetju odločbe v skladu s členom 17(3) Uredbe (ES) št. 1924/2006.
However, for applications which were not made before 19 January 2008 the requirement provided for in Article 28(6)(b) is not fulfilled, and the transition period laid down in that Article is not applicable.
Za vloge, ki niso bile predložene pred 19. januarjem 2008, zahteva iz člena 28(6)(b) ni izpolnjena, zato se prehodno obdobje iz navedenega člena ne uporablja.
Accordingly, a transition period of six months should be provided for, to enable food business operators to adapt to the requirements laid down in this Regulation.
Zato je treba določiti šestmesečno prehodno obdobje, da se nosilci živilske dejavnosti lahko prilagodijo zahtevam iz te uredbe.
The health claims set out in Annex II to this Regulation shall not be included in the Community list of permitted claims as provided for in Article 14(1) of Regulation (EC) No 1924/2006.
Zdravstvene trditve iz Priloge II k tej uredbi se ne uvrstijo na seznam dovoljenih trditev Skupnosti v skladu s členom 14(1) Uredbe (ES) št. 1924/2006.
However, they may continue to be used for six months after the entry into force of this Regulation.
Navedene zdravstvene trditve se lahko uporabljajo šest mesecev po začetku veljavnosti te uredbe.
The EFSA Journal (2008) 852, pp. 1-16.
The EFSA Journal (2008) 852, str. 1–16.
The EFSA Journal (2008) 895, pp. 1-10.
The EFSA Journal (2008) 895, str. 1–10.
The EFSA Journal (2008) 861, pp. 1-9.
The EFSA Journal (2008) 861, str. 1–9.
The EFSA Journal (2008) 860, pp. 1-8.
The EFSA Journal (2008) 860, str. 1–8.
The EFSA Journal (2008) 859, pp. 1-9.
The EFSA Journal (2008) 859, str. 1–9.
The EFSA Journal (2008) 863, pp. 1-8.
The EFSA Journal (2008) 863, str. 1–8.
The EFSA Journal (2008) 862, pp. 1-2.
The EFSA Journal (2008) 862, str. 1–2.
The EFSA Journal (2008) 902, pp. 1-9.
The EFSA Journal (2008) 902, str. 1–9.
The EFSA Journal (2008) 896, pp. 1-9.
The EFSA Journal (2008) 896, str. 1–9.
The EFSA Journal (2008) 897, pp. 1-10.
The EFSA Journal (2008) 897, str. 1–10.
The EFSA Journal (2008) 898, pp. 1-2.
The EFSA Journal (2008) 898, str. 1–2.
The EFSA Journal (2008) 899, pp. 1-10.
The EFSA Journal (2008) 899, str. 1–10.
The EFSA Journal (2008) 900, pp. 1-2.
The EFSA Journal (2008) 900, str. 1–2.
The EFSA Journal (2008) 901, pp. 1-8.
The EFSA Journal (2008) 901, str. 1–8.
The EFSA Journal (2008) 903, pp. 1-8.
The EFSA Journal (2008) 903, str. 1–8.
The EFSA Journal (2008) 904, pp. 1-2.
The EFSA Journal (2008) 904, str. 1–2.
EFSA opinion reference
Referenčno mnenje Agencije za varnost hrane
Article 14(1)(a) health claim referring to a reduction of a disease risk
Zdravstvena trditev po členu 14(1)(a), ki se nanaša na zmanjšanje tveganja za nastanek bolezni
Leaf Int and Leaf Holland, Hoevestein 26, 4903 SC Oosterhout NB, The Netherlands, and Leaf Suomi Oy, PO Box 25, FI-21381 Aura, Finland
LEAF Int and Leaf Holland, Hoevestein 26, 4903 SC Oosterhout NB, Nizozemska, and Leaf Suomi Oy, PO Box 25, FI-21381 Aura, Finska
Chewing gum sweetened with 100 % xylitol
Žvečilni gumi, sladkan s 100-odstotnim ksilitolom
Chewing gum sweetened with 100 % xylitol has been shown to reduce dental plaque.
Žvečilni gumi, sladkan s 100-odstotnim ksilitolom, dokazano zmanjšuje zobne obloge.
High content/level of dental plaque is a risk factor in the development of caries in children
Velik obseg/delež zobnih oblog je dejavnik tveganja za razvoj kariesa pri otrocih.
Information to the consumer that the beneficial effect is obtained with a consumption of 2-3 g of chewing gum sweetened with 100 % xylitol at least 3 times per day after the meals
Informacija potrošniku, da se koristni učinek doseže z uživanjem 2–3 g žvečilnega gumija, sladkanega s 100-odstotnim ksilitolom, najmanj 3 krat na dan po obroku.
Article 14(1)(b) health claim referring to children’s development and health
Zdravstvena trditev po členu 14(1)(b), ki se nanaša na razvoj in zdravje otrok
Danone SA, C/Buenos Aires, 21, 08029 Barcelona, Spain
DANONE S.A., C/Buenos Aires, 21, 08029 Barcelona, Španija
Phosphorus is needed for the normal growth and development of bone in children
Fosfor je potreben za normalno rast in razvoj kosti pri otrocih.
The claim can be used only for food which is at least a source of phosphorus as referred to in the claim SOURCE OF [NAME OF VITAMIN/S] AND/OR [NAME OF MINERAL/S] as listed in the Annex to Regulation (EC) No 1924/2006
Trditev se lahko navede le na živilu, ki je vsaj vir fosforja, kakor je opredeljeno s trditvijo VIR [IME VITAMINA/VITAMINOV] IN/ALI [IME MINERALA/MINERALOV] iz Priloge k Uredbi 1924/2006.
Lactoral helps to bring back the normal functioning of the alimentary tract during its microflora disturbances (for example in case of loose stools, after taking antibiotics, in case of intestinal disorders caused by enteric pathogens)
LACTORAL pomaga pri vzpostavitvi normalnega delovanja prebavil pri motnjah mikroflore (npr. pri driski, po uživanju antibiotikov, v primeru črevesnih bolezni).
Lactoral is recommended in order to improve the general immunity by maintaining the microbiological balance
LACTORAL je priporočljiv, ker z ohranjanjem mikrobiološkega ravnovesja krepi splošno odpornost.
Lactoral helps to protect the alimentary system against enteric pathogens because of strong antagonistic properties and helps to build the natural intestinal barrier
LACTORAL zaradi močnih antagonističnih lastnosti pomaga ščititi prebavni sistem pred črevesnimi povzročitelji bolezni in pomaga pri razvoju naravne črevesne pregrade.
Lactoral helps to maintain natural intestinal microflora during travel, changing the climatic zone or a diet, especially in poor hygiene conditions
LACTORAL pomaga ohranjati naravno črevesno mikrofloro med potovanjem, pri spremembi podnebja ali prehrane, zlasti v slabih higienskih razmerah.
Lactoral contains living probiotic bacteria with strong ability to intestinal tract colonisation, isolated from healthy, naturally fed infant
LACTORAL vsebuje žive probiotične bakterije z močno sposobnostjo črevesnega koloniziranja, izolirane pri zdravem, naravno hranjenem dojenčku.
Mumomega® provides the nourishments that support healthy central nervous system development
Mumomega® omogoča prehrano, ki spodbuja razvoj zdravega centralnega živčnega sistema.
Efalex® may help maintain coordination
Efalex® lahko pomaga ohranjati koordinacijo.
Efalex® may help maintain concentration
Efalex® lahko pomaga ohranjati zbranost.
Efalex® may help maintain and support brain development and function
Efalex® lahko pomaga ohranjati in spodbujati razvoj in delovanje možganov.
Efalex® may help maintain learning ability
Efalex® lahko pomaga ohranjati sposobnost učenja.
Efalex® may help maintain and support eye development and function
Efalex® lahko pomaga ohranjati ter spodbujati razvoj in delovanje oči.
Eye q baby® provides the nourishments that support healthy central nervous system development
Eye q baby® omogoča prehrano, ki spodbuja razvoj zdravega centralnega živčnega sistema.
Eye q® provides the nourishments that help children to maintain healthy brain functions
Eye q® omogoča prehrano, ki otrokom pomaga ohranjati zdravo delovanje možganov.
Eye q® provides the nourishments that help children to maintain concentration levels
Eye q® omogoča prehrano, ki otrokom pomaga ohranjati zbranost.
Commission Regulation (EC) No 1025/2009
Uredba Komisije (ES) št. 1025/2009
Pursuant to Regulation (EC) No 1924/2006 health claims made on food are prohibited unless they are authorised by the Commission in accordance with that Regulation and included in a list of permitted claims.
V skladu z Uredbo (ES) št. 1924/2006 so zdravstvene trditve na živilih prepovedane, razen če jih Komisija v skladu z navedeno uredbo odobri in uvrsti na seznam dovoljenih trditev.
Following an application from Elvir SAS, submitted on 30 July 2008 pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of a dairy product enriched with milk peptide and magnesium on the reduction of anxiety (Question No EFSA-Q-2008-476) [2].
Družba ELVIR S.A.S. je 30. julija 2008 v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki mlečnega proizvoda, obogatenega z mlečnim peptidom in magnezijem, na zmanjševanje občutka tesnobe (vprašanje št. EFSA-Q-2008-476) [2].
The claim proposed by the applicant was worded as follows: ‘This product helps moderate signs of anxiety in mildly stress-sensitive adults due to its milk peptide and magnesium content’.
Vložnik je predlagal naslednjo trditev: „Ta proizvod zaradi vsebnosti mlečnega peptida in magnezija pomaga blažiti znake tesnobe pri odraslih, ki težje prenašajo stres“.
On 19 December 2008, the Commission and the Member States received the scientific opinion from the Authority which concluded that on the basis of the data presented, a cause and effect relationship was not established between the consumption of the constituents proposed to exert the claimed effect and the claimed effect.
Komisija in države članice so 19. decembra 2008 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem sestavin, ki naj bi učinkovale, kot navaja trditev, in navedeno trditvijo ni utemeljena.
Following an application from Unilever plc (UK) and Unilever NV (Netherlands) submitted on 7 July 2008, pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of black tea from Camellia Sinensis on help to focus attention (Question No EFSA-Q-2008-434) [3].
Družbi UNILEVER PLC. (Združeno kraljestvo) in UNILEVER N.V. (Nizozemska) sta 7. julija 2008 v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložili vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinki črnega čaja iz Camellia Sinensis na povečevanje zbranosti (vprašanje št. EFSA-Q-2008-434) [3].
The claim proposed by the applicant was worded as follows: ‘Black tea helps you to focus attention’.
Vložnika sta predlagala naslednjo trditev: „Črni čaj vam pomaga k večji zbranosti“.
On the 22 December 2008 the Commission and the Member States received the scientific opinion from the Authority which concluded that on the basis of the data presented, a cause and effect relationship was not established between the consumption of black tea from Camellia Sinensis and the claimed effect.
Komisija in države članice so 22. decembra 2008 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem črnega čaja iz Camellia Sinensis in navedeno trditvijo ni utemeljena.
The comments from the applicants and the members of the public received by the Commission, pursuant to article 16(6) of Regulation (EC) No 1924/2006, have been considered when setting the measures provided for in this Regulation.
Pri določanju ukrepov iz te uredbe so bile upoštevane pripombe, ki so jih vložniki in predstavniki javnosti poslali Komisiji v skladu s členom 16(6) Uredbe (ES) št. 1924/2006.
The health claims ‘This product helps moderate signs of anxiety in mildly stress-sensitive adults due to its milk peptide and magnesium content’, and ‘Black tea helps you to focus attention’ are health claims as referred to in Article 13(1)(b) of Regulation (EC) No 1924/2006.
Zdravstveni trditvi „Ta proizvod zaradi vsebnosti mlečnega peptida in magnezija pomaga blažiti znake tesnobe pri odraslih, ki težje prenašajo stres“ in „Črni čaj vam pomaga k večji zbranosti“ sta znanstveni trditvi po členu 13(1)(b) Uredbe (ES) št. 1924/2006.
Therefore they are both subject to the transition measures laid down in Article 28(6) of Regulation (EC) No 1924/2006.
Zanju zato veljajo prehodni ukrepi iz člena 28(6) Uredbe (ES) št. 1924/2006.
However, as the applications were not made before 19 January 2008, the requirement provided for in Article 28(6)(b) is not fulfilled and the transition period laid down in that Article is not applicable.
Ker vloge niso bile predložene pred 19. januarjem 2008, zahteva iz člena 28(6)(b) ni izpolnjena in se prehodno obdobje iz navedenega člena ne uporablja.
Accordingly, a transition period of 6 months should be provided for, to enable food business operators to adapt to the requirements laid down in this Regulation.
Zato je treba določiti šestmesečno prehodno obdobje, da se lahko nosilci živilske dejavnosti prilagodijo zahtevam iz te uredbe.
Health claims set out in the Annex to this Regulation shall not be included in the Community list of permitted claims as provided for in Article 13(3) of Regulation (EC) No 1924/2006.
V skladu s členom 13(3) Uredbe (ES) št. 1924/2006 se zdravstvene trditve iz Priloge k tej uredbi ne uvrstijo na seznam dovoljenih trditev Skupnosti.
However, the health claims set out in the Annex to this Regulation may continue to be used for 6 months after the entry into force of this Regulation.
Zdravstvene trditve iz Priloge k tej uredbi se lahko uporabljajo še šest mesecev po začetku veljavnosti te uredbe.
The EFSA Journal (2008) 905, 1-10.
The EFSA Journal (2008) 905, str. 1–10.
The EFSA Journal (2008) 906, 1-10.
The EFSA Journal (2008) 906, str. 1–10.
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
Zdravstvena trditev po členu 13(5), ki je utemeljena na novo ugotovljenih znanstvenih dokazih in/ali vključuje zahtevo za zakonsko zaščito podatkov
Dairy product enriched with milk peptide and magnesium
mlečni proizvod, obogaten z mlečnim peptidom in magnezijem
This product helps moderate signs of anxiety in mildly stress-sensitive adults due to its milk peptide and magnesium content
Ta proizvod zaradi vsebnosti mlečnega peptida in magnezija pomaga blažiti znake tesnobe pri odraslih, ki težje prenašajo stres.
Black tea from Camellia Sinensis
črni čaj iz Camellia Sinensis
Black tea helps you to focus attention
Črni čaj vam pomaga k večji zbranosti.
Commission Regulation (EC) No 1026/2009
Uredba Komisije (ES) št. 1026/2009
correcting Regulation (EC) No 567/2009 entering a name in the register of traditional specialities guaranteed (Pierekaczewnik (TSG))
o popravkih Uredbe Komisije (ES) št. 567/2009 o registraciji imena v register zajamčenih tradicionalnih posebnosti (Pierekaczewnik (ZTP))
An error was found in the publication of Commission Regulation (EC) No 567/2009 [2] registering the name ‘Pierekaczewnik’ as a traditional speciality guaranteed.
V objavi Uredbe Komisije (ES) št. 567/2009 [2], ki ureja registracijo označbe „Pierekaczewnik“ kot zajamčene tradicionalne posebnosti, je prišlo do napake.
In line with the request submitted by Poland, this name should be granted the protection provided for in Article 13(2) of Regulation (EC) No 509/2006.
V skladu z zahtevo Poljske bi bilo treba po členu 13(2) Uredbe (ES) št. 509/2006 to označbo zaščititi.
Regulation (EC) No 567/2009 should therefore be amended accordingly,
Uredbo (ES) št. 567/2009 je zato treba ustrezno popraviti –
Regulation (EC) No 567/2009 is hereby corrected as follows:
Uredba (ES) št. 567/2009 se spremeni:
the third recital is replaced by the following:
Uvodna izjava 3 se nadomesti z naslednjim:
When the application for registration was submitted, the protection provided for in Article 13(2) of Regulation (EC) No 509/2006 was also requested.
Hkrati z zahtevo za registracijo je bilo prav tako zaprošeno za zaščito iz člena 13(2) Uredbe (ES) št. 509/2006.
That protection should be granted to the name “Pierekaczewnik” in so far as, in the absence of objections, it could not be demonstrated that the use of the name is lawful, renowned and economically significant for similar agricultural products or foodstuffs.’;
Označbo ‚Pierekaczewnik‘ je zato smiselno zaščititi, ker ni bilo nasprotovanj in ni bilo mogoče ovreči, da se ime za podobne kmetijske proizvode in živila uporablja na zakonit, splošno znan in gospodarsko pomemben način.“
the following paragraph is added to Article 1:
Členu 1 se doda naslednji odstavek:
‘The protection provided for in Article 13(2) of Regulation (EC) No 509/2006 shall apply.’;
„Uporabi se zaščita iz člena 13(2) Uredbe (ES) št. 509/2006.“
in the Annex, the following is added:
V Prilogi se doda naslednje:
‘The use of the name is reserved.’.
„Uporaba imena je pridržana.“